Bannerbild German Brest Group - Forschung

Übersicht über Kongressbeiträge von 2016

Mitglieder der German Breast Group präsentierten im Jahr 2016 folgende Beiträge auf internationalen Kongressen:

Poster presented at SABCS 2015

SABCS 2016 San Antonio

Denkert C, von Minckwitz G, Darb-Esfahani S, Ingold Heppner B, Klauschen F, Furlanetto J, Pfitzner B, Huober J, Schmitt W, Blohmer J-U, Kümmel S, Engels K, Lederer B, Schneeweiss A, Hartmann A, Jakisch C, Untch M, Hanusch C, Weber K, Loibl S: Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 3771 patients. Oral presentation S1-09, SABCS 2016

Bidard F-C, Michiels S, Mueller V, Riethdorf S, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothe F, Smerage J, Muinelo L, Stebbing J, Viens P, Magbanua M, Hall CS, Engebråtenm O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran F-A, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf D, Bowman Bauldry J, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Ruud R, Tokiniwa H, Llombart-Cussac A, D'Hollander K, Cottu P, Park JW, Loibl S, Pierga J-Y, Pantel K: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy. Oral presentation S3-01, SABCS 2016

von Minckwitz G, Timms K, Untch M, Elkin EP, Hahnen E, Fasching PA, Schneeweiss A, Salat CT, Rezai M, Blohmer J-U, Zahm D-M, Jackisch C, Gerber B, Klare P, Kümmel S, Paepke S, Schmutzler R, Chau S, Reid J, Hartman A-R, Nekljudova V, Weber KE, Loibl S: Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Poster P1-09-02, SABCS 2016

van Mackelenberg M, Denkert C, Nekljudova V, Karn T, Schem C, Marme F, Stickeler E, Jackisch C, Hanusch C, Huober J, Fasching P, Blohmer J-U, Kümmel S, Müller V, Schneeweiss A, Untch M, von Minckwitz G, Weber K, Loibl S: Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Poster P1-09-11, SABCS 2016

van Mackelenbergh M, Loibl S, Jackisch C, Lück H-J, Schneeweiss A, Tesch H, Harbeck N, Schmatloch S, Fehm T, Huober J, Müller V, Bauerfeind I, Untch M, von Minckwitz G, Nekljudova V, Möbus V: Efficacy and safety of darbepoetin alfa or epoetin beta in 2994 high risk early breast cancer patients participating in the German adjuvant intergroup node-positive study (GAIN). Poster P2-11-04, SABCS 2016

Loibl S, Pfarr N, Weber K, Neunhöffer T, Villegas S, Stenzinger A, Furlanetto J, Aktas B, Budczies J, Marmé F, Kahmann L, Denkert C, Weichert W: Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls. Poster P2-03-09, SABCS 2016

Liedtke C, Kolberg H-C, Kerschke L, Goerlich D, Bauerfeind I, Fehm T, Fleige B, Hauschild M, Helms G, Lebeau A, Schmatloch S, Schrenk P, Schwentner L, Staebler A, von Minckwitz G, Loibl S, Untch M, Kuehn T: Development and validation of a nomogram predicting pathological axillary status (ypN0 vs. ypN+) in a subgroup of patients converting from cN+ to ycN0 through neoadjuvant therapy (NAT) - A transSENTINA substudy. Poster P3-13-06, SABCS 2016

Loibl S, Jackisch J, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kuemmel S, Luebbe K, Warm M, Just M, Hanusch C, Hackmann J, Blohmer J-U, Clemens M, Engels K, Nekljudova V, von Minckwitz G, Untch M: Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial. Poster P4-21-06, 2016

Furlanetto J, von Minckwitz G, Jackisch C, Schneeweiss A, Aktas B, Denkert C, Wiebringhaus H, Kuemmel S, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer J-U, Clemens M, Costa SD, Gerber B, Nekljudova V, Untch M, Loibl S: Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 69). Poster P5-16-03, SABCS 2016

ESMO 2016 Copenhagen

S. Loibl, A. Schneeweiss, N. Burchardi, J.-U. Blohmer, C. Hanusch, S. Costa, J. Huober, C. Jackisch, G. von Minckwitz, S. Kümmel, S. Paepke, C. Denkart, M. Untch: A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4673 (durvalumab) to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (GeparNuevo), ESMO 2016, 221TiP

S. Loibl, A. Demichele, N. Turner, M. Cristofanilli, S. Loi, S. Verma, H. Bhattacharyya, Z. Ke, C. Giorgetti, C. Bartlett, S. Iyer, M. Colleoni, N. Masuda, S.-A. Im, N. Harbeck: Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR + , HER2- metastatic breast cancer, ESMO 2016, 260P

J. Bischoff, J. Barinoff, C. Mundhenke, D. Bauerschlag, S. Costa, D. Herr, K. Lübe, F. Marmé, N. Maass, G. von Minckwitz, E.-M. Grischke, V. Müller, M. Schmidt, B. Gerber, S. Kümmel, C. Schumacher, P. Krabisch, M. Thill, V. Nekljudova, S. Loibl: A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita, ESMO 2016, 273P

F. André, B. Kaufman, D. Juric, E. Ciruelos, H. Iwata, I. Mayer, P. Conte, H.S. Rugo, S. Loibl, G. Rubovszky, H. Tesch, K. Inoue, Y.-S. Lu, L. Ryvo, A.-S. Longin, D. Mills, C. Wilke, C. Germa, M. Campone: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1), ESMO 2016, 311TiP

G. Curigliano, S. Loibl, V. Müller, X. Pivot, A. Wardley, D. Cameron: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC), ESMO 2016, 312TiP

ASCO 2016 Chicago

Von Minckwitz G, Steffen J, Costa SD, Janni W, Thill M, Müller V, Neunhoeffer T, Lenhard HG, Feisel G, Schrader I, Kullmer U.E, Wittenberg M, Nekljudova V, Loibl S, German Breast Group: Quality of patient-reported outcome for long-term survival of early breast cancer trials. J Clin Oncol 34, 2016 (suppl; abstr e18121), ASCO 2016 Chicago

Kümmel S, von Minckwitz G, Nekljudova V, Costa SC, Denkert C, Hanusch C, Huober J, Jackisch C, Paepke S, Blohmer JU, Untch M, Schneeweiss A, Loibl S, German Breast Group: Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX). J Clin Oncol 34, 2016 (suppl; abstr TPS635), ASCO 2016 Chicago

Andre F, Campone M, Ciruelos EM, Iwata H, Loibl S, Rugo H, Wilke C, Mills D, Chol M, Longin A.S, Juric D: SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2– advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy. J Clin Oncol 34, 2016 (suppl; abstr TPS618), ASCO 2016 Chicago

Denkert D, Weber K, Krappmann K, Huober J, Marmé F, Schem C, Engels K, Pfitzner B.M, Kummel S, Furlanetto J, Hartmann A, Darb-Esfahani S, Mueller F, Staebler A, Mehta K, von Minckwitz G, Kronenwett R, Loibl S: Risk assessment after neoadjuvant chemotherapy in luminal breast cancer: A prospectively planned validation of gene expression based and clinical prognostic scores in 428 residual tumor samples from two neoadjuvant clinical trials. J Clin Oncol 34, 2016 (suppl; abstr 522), ASCO 2016 Chicago

Bergh J, Foukakis T, von Minckwitz G, Bengtsson N.O, Wallberg B, Fornander T, Mlineritsch B, Schmatloch S, Singer C. F, Steger G.G, Karlsson E, Carlsson L, Loibl S, Untch M, Hellstrom M, Johansson H, Malmstrom P, Gnant M, Greil R, Moebus V: PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy. J Clin Oncol 34, 2016 (suppl; abstr 1002), ASCO 2016 Chicago

Fasching P.A, Blohmer J.U, Burchardi N, Costa S.D, ,Denkert C, Hanusch C, Huober J.B, von Minckwitz G, Paepke S, Schneeweiss A, Kümmel S, Untch M, Loibl S, Jackisch C: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin / cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA. J Clin Oncol 34, 2016 (suppl; abstr TPS1096), ASCO 2016 Chicago

Schwentner L, Helms G, Nekljudova V, Ataseven B, Bauerfeind I, Ditsch N, Fehm T, Fleige B, Hauschild M, Heil J, Kümmel S, Lebeau A, Liedtke C, Loibl S, Schmatloch S, Schrenk P, Staebler A, Untch M, von Minckwitz G, Kühn T; Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy: Results from the prospective multi-center SENTINA trial. J Clin Oncol 34, 2016 (suppl; abstr 1054), ASCO 2016 Chicago

Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Eulenburg C, Schem C, Fasching P. A, Karn T, Fehm T, Kühn T, Overkamp F, Rack B, Denkert C, Untch M, Pantel K, Bokemeyer C, Loibl S, von Minckwitz, Loges S: Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial. J Clin Oncol 34, 2016 (suppl; abstr 11505), ASCO 2016 Chicago

Fontanella C, Lederer B, Del Mastro L, Denkert C, De Placido S, Hanusch C, Cognetti F, Huober J, De Laurentiis M, Jackisch C, Bisagni G, Kummel S, Garrone O, Schneeweiss A, Montemurro F, Untch M, Bighin C, von Minckwitz G, Loibl S,Puglisi F; Development and validation of a new prognostic score on 4,646 patients with luminal-like breast cancer (BC) enrolled in 7 randomized prospective trials. J Clin Oncol 34, 2016 (suppl; abstr 529), ASCO 2016 Chicago

Loibl S, Turner N. C, Ro J, Cristofanilli M, Iwata H, Im S. A, Masuda N, Loi S, Andre F, Harbeck N, Verma S, Folkerd E, Theall K.P, Zhang K, Huang Bartlett C, Dowsett N: Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy – results from Paloma-3. J Clin Oncol 34, 2016 (suppl; abstr 524), ASCO 2016 Chicago

Turner N. C, Jiang Y, O'Leary B, Hrebien S, Cristofanilli M, Andre F, Loibl S, English P. A, Zhang K, Randolph S, Huang Bartlett C, Koehler M, Loi S: ; Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA). J Clin Oncol 34, 2016 (suppl; abstr 512), ASCO 2016 Chicago

Valentina Nekljudova, Sibylle Loibl, Gunter Von Minckwitz, Stefan Gluck, Richard Crane, Huiling Li, Xiaolong Luo: A model for trial level prediction of long term outcome based on pathological complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC). J Clin Oncol 34, 2016 (suppl; abstr 1031)

Volkmar Mueller, Sibylle Loibl, Elena Laakmann, Doris Augustin, Felix Flock, Hans Hermann Dohmen, Strittmatter Hans-Joachim, Matthias Frank, Tobias Hesse, Atanas Ignatov, Thorsten Kuehn, Tjoung-Won Park-Simon, Marcus Schmidt, Florian Wuerschmidt, Tanja N. Fehm, Volker Moebus, Gunter Von Minckwitz, Nicole Burchardi, Isabell Witzel: Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): Treatment patterns and clinical outcome of more than 1000 patients with brain metastases from breast cancer. J Clin Oncol 34, 2016 (suppl; abstr 2070)

AACR 2016 New Orleans

Loibl S, Budczies J, Weichert W, Furlanetto J, Stenzinger A, Pfarr N, von Minckwitz G, Jackisch C, Schneeweiss A, Fasching P, Schmatloch S, Aktas B, Nekljudova V, Weber K, Untch U, Denkert C: Prediction of therapy resistance by targeted massive-parallel sequencing in primary HER2-positive breast cancer. Abstract Number: 5010, Poster Session, AACR 2016 New Orleans

EBCC 2016 Amsterdam

S. Paepke, J. Huober, K. Sherko, H. Eidtmann, M. Untch, S. Dan Costa, J.U. Blohmer, W. Eiermann, B. Gerber, C. Hanusch, J. Hilfrich, C. Jackisch, A. Schneeweiss, C. Denkert, K. Engels , P. Klare, P. Fasching, N. Burchardi, S. Loibl, G. von Minckwitz: Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE). European Journal of Cancer 57, suppl. 2 (2016) S19–S153, Abstract number: 350, EBCC 2016 Amsterdam

DKK 2016 Berlin

B. Ingold Heppner, M. Untch, C. Denkert, B. M. Pfitzner, B. Lederer, W. Schmidt, H. Eidtmann, P. Fasching, H. Tesch, C. Solbach, M. Rezai, D.- M. Zahm, F. Holms, M. Glados, P. Krabisch, E. Heck, A. Ober, P. Lorenz, K. Diebold, J. Habeck, S. Loibl: Tumor-infiltrating lymphocytes and response prediction to neoadjuvant chemotherapy in HER2-positive breast cancer. Oncol Res Treat 2016;39(suppl 1):1–175, Abstract Nr. 512, Seite 5, DKK 2016 Berlin

E. Laakmann, I. Witzel, T. Fehm, T. Hesse, G. von Minckwitz, V. Möbus, T.-W. Park-Simon, T. Neunhöffer, M. Schmidt, S. Loibl, V. Müller: Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): The introduction of the multicenter register and analysis of patient data. Oncol Res Treat 2016;39(suppl 1):1–175, Abstract Nr. 236, Seite 50, DKK 2016 Berlin

B. Pfitzner, B. Lederer, J. Lindner, C. Solbach, K. Engels, M. Rezai, K. Dohnal, H. Tesch, M.- L. Hansmann, C. Salat, M. Beer, A. Schneeweiss, P. Sinn, G. von Minckwitz, C. Denkert, S. Loibl: HER2 testing in neoadjuvant breast cancer trials – improved concordance of HER2 status in different pathology laboratories. Oncol Res Treat 2016;39(suppl 1):1–175, Abstract Nr. 496, Seite 56, DKK 2016 Berlin

V. Möbus, H.- J. Lück, H. Forstbauer, G. Wachsmann, A. Ober, A. Schneeweiss, B. Christensen, E. von Abel, E.- M. Grischke, H.-G. Höffkes, P. Klare, Y.- D: GAIN2: Adjuvant phase III trial comparing an intensified dose-dense (idd) adjuvant therapy with EnPC compared to a dose-dense (dd), dose-adapted therapy with dtEC-dtD in patients with primary high risk breast cancer: Results of the second safety interim analysis. Oncol Res Treat 2016;39(suppl 1):1–175, Abstract Nr. 560, Seite 57, DKK 2016 Berlin

M. Untch, G. von Minckwitz, C. Jackisch, A. Schneeweiss, B. Conrad , B. Aktas, C. Denkert, H. Eidtmann, H. Wiebringhaus, S. Kümmel, J. Hilfrich, M. Warm, S. Paepke, M. Just, C. Hanusch, J. Hackmann, J. Uwe Blohmer, M. Clemens, S. Dan Costa, B. Gerber, V. Nekljudova, S. Loibl: nab-Paclitaxel at a dose of 125 mg/m² weekly is more efficacious but less toxic than at 150 mg/m². Results from the neoadjuvant randomized GeparSepto study (GBG 69). Oncol Res Treat 2016;39(suppl 1):1–175, Abstract Nr. 561, Seite 58, DKK 2016 Berlin

J. Furlanetto, W. Eiermann, F. Marmé, T. Reimer, M. Reinisch, S. Schmatloch, E. Stickeler, C. Thomssen, M. Untch, C. Denkert, G. von Minckwitz, V. Nekljudova, V. Möbus, S. Loibl: Higher Rate of Severe Toxicities in Obese Patients Receiving dose-dense (dd) Chemotherapy according to Unadjusted Body Mass Index – Results of the Prospectively Randomized GAIN study. Oncol Res Treat 2016;39(suppl 1):1–175, Abstract Nr. 562, Seite 58, DKK 2016 Berlin

J. Budczies, N. Pfarr, A. Stenzinger, D. Treue, V. Endris, F. Ismaeel, N. Bangemann, J.- U. Blohmer, M. Dietel, S. Loibl, W. Weichert, C. Denkert: Ioncopy: A novel method for calling copy number alterationsin amplicon sequencing data including significance assessment. Oncol Res Treat 2016;39(suppl 1):1–175, Abstract Nr. 460, Seite 123, DKK 2016 Berlin


Lejla Valjevcic

Tel.: +4961027480418

Fax: +4961027480118

E-Mail: Pblctngbgd

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd